The costs of treating glaucoma with combinations of topical drugs in Spain

European Journal of Ophthalmology

Volumn 18, Issue 1, 2008, Pages 52-59

  Neymark, Niels ^a,f   Buchholz, P ^b   Honrubia, F ^c   Kobelt, G ^d,e  

^a PharmAllergan GmbH ^*

^b IDS SCHEER AG   (Germany)

^c Hospital Miguel Servert   (Spain)

^d LUND UNIVERSITY   (Sweden)

^e European Health Economics   (France)

^f NONE   (Belgium)

Author keywords

Combination therapy; Cost analysis; Glaucoma treatment; Spanish costs

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BIMATOPROST PLUS TIMOLOL; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

ARTICLE; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST; COST BENEFIT ANALYSIS; DATA EXTRACTION; DRUG COST; FEMALE; FOLLOW UP; GLAUCOMA; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SPAIN; STATISTICAL SIGNIFICANCE; TOPICAL TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 41149174879     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800109     Document Type: Article

References (9)

1. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40.
2. Heijl A, Leske CM, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-79.
3. Holmström S, Buchholz P, Walt J, et al. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries. Curr Med Res Opin 2006; 22: 897-905.
4. Krieglstein GK. Die grossen Therapiestudien zum Glaukom. Der Ophthalmologe 2003; 100: 484-91.
5. Jönsson B, Krieglstein G, eds. Primary open-angle glaucoma. Differences in international treatment patterns and costs. Oxford: ISIS Medical Media, 1999.
6. Kobelt G, Jönsson L. Markov model. In: Jönsson B, Krieglstein G, eds. Primary open-angle glaucoma. Differences in international treatment patterns and costs. Oxford: ISIS Medical Media, 1999.
7. Holmström S, Buchholz P, Walt J, et al. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin 2005; 21: 1875-83.
8. Lindblom B, Nordmann J-P, Seilern E, et al. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand 2006; 84: 74-83.
9. Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long-term study of resource utilization in Europe. Br J Ophthalmol 2005; 89: 1245-9.